Free preview. Sign up free to see the team, full portfolio, ownership chain, and shareholding history.
Mnl Nominees Ltd (As Nominee For&On Behalf Of Eos Innovation Fund) investment portfolio
Mnl Nominees Ltd (As Nominee For&On Behalf Of Eos Innovation Fund) has made numerous investments in companies such as Scarlet Therapeutics, Camgene Therapeutics, and Concinnity Genetics within the Biotech sector.
vc
Portfolio
3
Team
0
Portfolio (3)
| Company | Sector | City | Source | Last confirmed on |
|---|---|---|---|---|
| Camgene Therapeutics Limited CamGene Therapeutics Limited develops RNA‑based therapeutics aimed at treating hearing loss. | BiotechHealth Tech | Cambridge | Confirmed | 2025-06-06 |
| Concinnity Genetics Ltd Concinnity Genetics creates AI‑driven RNA‑based gene control systems that enhance the safety and efficacy of gene and cell therapies, offering its technology to biotechnology and pharmaceutical companies developing gene‑therapy treatments. | Healthcare & Life Sciences | Edinburgh | Confirmed | 2025-10-16 |
Backs Similar Companies
Investors who tend to invest in the same sort of companies.
5 more similar investors hiddenSign up to unlock →
Shareholding changes (3)
Mnl Nominees Ltd (As Nominee For&On Behalf Of Eos Innovation Fund)'s positions across portfolio companies2026
- B ORDINARY 0 → 219,198
- SERIES A 0 → 183,298
Articles (4)
- UKI2S takes 11.2% stake in Camgene Therapeutics Limited, RNA therapeutics firm2 Sept 2026Camgene Therapeutics
- Daft Capital Fund I LP takes 8.6% stake in Scarlet Therapeutics22 Aug 2026Scarlet Therapeutics
- Camgene Therapeutics secures £260k Series A funding for hearing loss treatments19 May 2026Camgene Therapeutics
- Scarlet Therapeutics secures £3.5m for metabolic disease platform9 May 2026Scarlet Therapeutics